ImmunityBio (IBRX) Short term Debt (2014 - 2021)

ImmunityBio (IBRX) has 8 years of Short term Debt data on file, last reported at $8.7 million in Q3 2021.

• Short term Debt for Q3 2021 came in at $8.7 million, up 541.37% year-over-year; the trailing twelve-month figure through Sep 2021 was $8.7 million (up 541.37% YoY), and the FY2020 annual result was $14.8 million, up 2953.09% from the prior year.
• Short term Debt eased to $8.7 million in Q3 2021 per IBRX's latest filing, from $16.7 million in the prior quarter.
• Over five years, Short term Debt peaked at $17.8 million in Q1 2021 and troughed at $486000.0 in Q4 2019.
• A 5-year average of $4.5 million and a median of $2.1 million in 2017 frame the typical range for Short term Debt.
• The sharpest annual moves came in 2019 and 2020: Short term Debt tumbled 71.34% in 2019, then soared 2953.09% in 2020.
• A 5-year view of Short term Debt shows it stood at $2.4 million in 2017, then fell by 28.23% to $1.7 million in 2018, then plunged by 71.34% to $486000.0 in 2019, then soared by 2953.09% to $14.8 million in 2020, then slumped by 41.39% to $8.7 million in 2021.
• Business Quant data shows IBRX's Short term Debt at $8.7 million in Q3 2021, $16.7 million in Q2 2021, and $17.8 million in Q1 2021.